OTLK Stock Forecast: Outlook Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Outlook Therapeutics, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 3 of 100 as at 18 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Outlook Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (34): Analysts have, on balance, been raising their forecasts.
Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
OTLK stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OTLK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Sept 2026 | Ascendiant Capital | Maintains | Buy | $10 → $11 |
| 14 Aug 2026 | BTIG | Reiterates | Buy | $4.00 |
| 27 July 2026 | BTIG | Upgrade | Buy | $4.00 |
| 27 July 2026 | HC Wainwright & Co. | Maintains | Neutral | $0.50 → $1.60 |
| 11 June 2026 | Ascendiant Capital | Maintains | Buy | $6.00 → $10 |
| 18 May 2026 | BTIG | Downgrade | Neutral | — |
| 11 Mar 2026 | Ascendiant Capital | Maintains | Buy | — |
| 18 Feb 2026 | Chardan Capital | Maintains | Neutral | — |
| 18 Feb 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 5 Jan 2026 | Chardan Capital | Maintains | Neutral | — |
| 2 Jan 2026 | HC Wainwright & Co. | Maintains | Neutral | — |
| 22 Dec 2025 | Ascendiant Capital | Maintains | Buy | — |
| 30 Sept 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 22 Sept 2025 | Ascendiant Capital | Maintains | Buy | — |
| 29 Aug 2025 | Guggenheim | Downgrade | Neutral | — |
| 29 Aug 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 28 Aug 2025 | Chardan Capital | Maintains | Neutral | — |
| 15 Aug 2025 | Chardan Capital | Maintains | Neutral | — |
| 6 June 2025 | Ascendiant Capital | Maintains | Buy | — |
| 24 Feb 2025 | Ascendiant Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OTLK.
This page is one stock. Monday covers all of them.
OTLK appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
OTLK vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Outlook Therapeutics, Inc. returned −79.5% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
OTLK analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- −99.4%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 1% of US stocks
- Return on equity
- —
- Return on assets
- −143.2%
- Dividend yield
- —
Higher than 1% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Outlook Therapeutics, Inc. has a market value of $87.9M and an enterprise value of $95.0M.
Revenue in the twelve months to 30 June 2026: −$1.2M. The latest quarter shrank 99.4% year on year.
Net income over the same four quarters: −$61.1M, a 5253.5% net margin.
Free cash flow in the twelve months to 30 June 2026: −$56.2M.
Outlook Therapeutics, Inc. employs 17 people — −$68K of revenue per employee.
Data provided by Twelve Data
OTLK and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at OTLK’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Outlook Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about OTLK
What is the OTLK stock price forecast for 2026-2027?
The median 12-month analyst price target for Outlook Therapeutics, Inc. is $4, with estimates ranging from $1.6 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OTLK stock a buy right now?
Of the 4 analysts covering Outlook Therapeutics, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Outlook Therapeutics, Inc. 3 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OTLK?
As at 18 Nov 2026, Outlook Therapeutics, Inc. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (34 of 100).
Will OTLK stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $4, and Ticker Nerd's factor model ranks Outlook Therapeutics, Inc. 3 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OTLK stock forecast for 2030?
No analyst covering Outlook Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OTLK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.6 to $11 over the next 12 months.
How has OTLK stock performed over the past year?
Outlook Therapeutics, Inc. returned -79.5% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Outlook Therapeutics, Inc. do?
Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for retinal diseases. Its principal product, LYTENAVA, is an ophthalmic formulation of bevacizumab designed for use in retinal indications, including wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion.
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for retinal diseases. Its principal product, LYTENAVA, is an ophthalmic formulation of bevacizumab designed for use in retinal indications, including wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion. The company’s activities span clinical development, regulatory operations, manufacturing coordination, and commercialization of specialized eye-care therapies. Outlook Therapeutics serves the ophthalmology and retinal-care markets, addressing conditions that can impair vision and require ongoing medical management. Its product platform is centered on monoclonal antibody treatment delivered specifically for ophthalmic use, supporting applications across retinal disease care. Based in Iselin, New Jersey, Outlook Therapeutics, Inc. occupies a specialized role within the biopharmaceutical sector by concentrating its operations on vision-related disorders and therapies intended for administration by eye-care professionals.
CEO Mr. Robert Charles Jahr · 17 employees · United States · https://outlooktherapeutics.com